News and Trends 9 Jul 2018 Swedish Alzheimer’s Treatment Slows the Disease in Phase II Trial BioArctic, based in Stockholm, has clinical results showing its antibody treatment that targets amyloid plaques, a hallmark of Alzheimer’s disease, can slow the disease’s progression. The trial tested the antibody in 856 patients with early-stage Alzheimer’s disease with plaques of amyloid-beta protein in their brains, which is considered a common hallmark of the disease. Results taken at […] July 9, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jul 2018 Abingworth Closes €268M to Invest in Life Science Companies Abingworth has closed $315M (€268M) for its most recent fund, Abingworth Bioventures VII, which invests in European and US life science companies. In the current fundraising, Abingworth surpassed its target of $300M. The new fund will invest in life science companies in all stages of development, including early and late-stage venture deals. The company plans to […] July 9, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jul 2018 A New HIV Vaccine Could Protect Patients Against Multiple Viral Strains A new HIV vaccine is moving into a Phase IIb trial and could potentially protect patients against multiple HIV strains worldwide. Recent findings from a Phase I/IIa trial published in The Lancet show that a new HIV-1 vaccine was safe and produced an immune response against HIV 393 healthy adults, as well as in a […] July 6, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2018 Series A Round Could Bring French Microbiome Treatment for Bowel Disease Into the Clinic Netbiotix has raised €7.5M to bring its lead candidate for inflammatory bowel disease into clinical trials. The treatment uses a bacterium found in the gut to prevent and dampen inflammation. The company, based in Paris, develops treatments for inflammatory bowel disease (IBD) that consist of a single microbial strain that interacts with cells in the […] July 5, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2018 Stem Cells Could Help Patients Recover From Heart Attacks Viscofan BioEngineering has a green light in Spain to start clinical testing for its stem cell technology in patients with weakened heart muscles after a heart attack. While Viscofan BioEngineering’s main focus is on making sausage casings out of collagen, its technology could also help patients with weak heart muscles after suffering from a heart […] July 4, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jul 2018 French Lupus Vaccine Ready to Move Into Phase III Neovacs, a French biotech, has shown its lupus vaccine can be effective in treating this severe autoimmune disease. Its lupus vaccine works by stimulating the patient’s immune system to produce antibodies against a protein called IFNα that regulates the immune system and is involved in the disease. The study enrolled 185 patients around the globe […] July 3, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jul 2018 Dutch Snake Venom-Derived Clotting Agent Comes Closer to the Clinic Dutch biotech raises €12.5M to complete the preclinical development of its lead compound for acute internal bleeding and bring the drug into clinical trials. VarmX, based in Leiden, the Netherlands, raised a Series A round of €7.5M led by BioGeneration Ventures, with an additional €5M provided by the Netherlands Enterprise Agency as an Innovation Credit. The […] July 2, 2018 - 1 minutemin - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2018 Glass Microbiology: From the Microscope to the Art Gallery Artist Luke Jerram is behind Glass Microbiology, a series of beautiful glass-blown microbes that are changing the way we perceive viruses and bacteria. We’ve all seen at some point brightly-colored illustrations of viruses, most likely the feared HIV or an alien-like bacteriophage. These representations feed our imagination and help us understand the tiny but complex world of […] June 30, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2018 Update: Yet Another ADC Company Makes Bank, This Time in Series B Update (29.06.2018): NBE Therapeutics has extended its Series B fundraising round by 20M CHF (€17.3M), reaching a total of 40M CHF (€34.6M) for the round. Novo Holdings joins the Boehringer Ingelheim Venture Fund and the PPF Capital Partners Fund as a major shareholder of the Swiss biotech, which continues to develop its ADCs for improved […] June 29, 2018 - 3 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2018 Muscular Dystrophy Drug Fails in Phase 2 Trial The stock of Summit Therapeutics has plunged by 80% after announcing that its drug candidate for Duchenne muscular dystrophy failed to meet the primary and secondary endpoints of a Phase II clinical trial. Duchenne muscular dystrophy is a genetic disease that causes progressive muscle deterioration in children born with the disease. The British-American company Summit […] June 28, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jun 2018 International Fund Raises €300M for Dementia Research The Dementia Discovery Fund has raised $350M (€300M) to support industrial and academic scientists doing early-stage research to develop new dementia medicines. Launched in 2015, the Dementia Discovery Fund (DDF) is dedicated to investing in early-stage ventures that develop disease-modifying therapeutics for all types of dementia, including Alzheimer’s and Parkinson’s. Yesterday, the DDF completed a […] June 27, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jun 2018 Update: The FDA Approves First Cannabinoid Treatment for Epilepsy Update (26/06/2018): The FDA has approved GW Pharmaceutical’s drug Epidiolex in two severe forms of epilepsy. The approval makes Epidolex the first prescription drug made from highly purified cannabidiol to reach the market. Published on 20/04/2018 GW Pharmaceuticals has received a unanimous recommendation from the FDA Advisory Committee Meeting supporting the approval of what could soon […] June 26, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email